UA89780C2 - Способ лечения или облегчения симптомов атеросклероза с помощью анти-cd3 антитела - Google Patents

Способ лечения или облегчения симптомов атеросклероза с помощью анти-cd3 антитела

Info

Publication number
UA89780C2
UA89780C2 UAA200611467A UAA200611467A UA89780C2 UA 89780 C2 UA89780 C2 UA 89780C2 UA A200611467 A UAA200611467 A UA A200611467A UA A200611467 A UAA200611467 A UA A200611467A UA 89780 C2 UA89780 C2 UA 89780C2
Authority
UA
Ukraine
Prior art keywords
atherosclerosis
antibody
treating
alleviating symptoms
alleviating
Prior art date
Application number
UAA200611467A
Other languages
English (en)
Ukrainian (uk)
Inventor
Бернар Мах
Ян Дин
Мари Коско-Вильбуа
Original Assignee
Новиммюн С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новиммюн С.А. filed Critical Новиммюн С.А.
Publication of UA89780C2 publication Critical patent/UA89780C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Изобретение относится к способу лечения или облегчения симптомов атеросклероза, а также способа подавления образования атеросклеротических бляшек на артериях с помощью анти-CD3 антитела.
UAA200611467A 2004-04-06 2005-04-06 Способ лечения или облегчения симптомов атеросклероза с помощью анти-cd3 антитела UA89780C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55994404P 2004-04-06 2004-04-06

Publications (1)

Publication Number Publication Date
UA89780C2 true UA89780C2 (ru) 2010-03-10

Family

ID=35150504

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200611467A UA89780C2 (ru) 2004-04-06 2005-04-06 Способ лечения или облегчения симптомов атеросклероза с помощью анти-cd3 антитела
UAA200907841A UA103594C2 (ru) 2004-04-06 2005-04-06 Способ лечения увеита

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA200907841A UA103594C2 (ru) 2004-04-06 2005-04-06 Способ лечения увеита

Country Status (20)

Country Link
US (1) US20050265993A1 (ru)
EP (1) EP1737490B1 (ru)
JP (1) JP4812748B2 (ru)
KR (1) KR20070036035A (ru)
CN (2) CN1972714B (ru)
AT (1) ATE470453T1 (ru)
AU (1) AU2005232653B2 (ru)
CA (1) CA2563260C (ru)
DE (1) DE602005021766D1 (ru)
DK (1) DK1737490T3 (ru)
EA (1) EA012725B1 (ru)
ES (1) ES2348984T3 (ru)
HK (1) HK1099525A1 (ru)
IL (2) IL178478A (ru)
MX (1) MXPA06011526A (ru)
NO (2) NO340627B1 (ru)
PT (1) PT1737490E (ru)
UA (2) UA89780C2 (ru)
WO (1) WO2005099755A2 (ru)
ZA (1) ZA200608884B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4939899B2 (ja) * 2006-10-30 2012-05-30 オムロンオートモーティブエレクトロニクス株式会社 導電端子の溶接方法、および導電端子構造
WO2008119567A2 (en) † 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
JP2013526594A (ja) * 2010-05-24 2013-06-24 インデナ エッセ ピ ア 微生物感染の治療に使用するためのタマリンド種子多糖
EP2640750A1 (en) * 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents and methods for treating diseases that correlate with bcma expression
JP2015091761A (ja) * 2012-02-23 2015-05-14 国立大学法人大阪大学 中枢神経の損傷を治療するための組成物およびその利用
US9664690B1 (en) * 2013-08-28 2017-05-30 The National Institute For Biotechnology I Molecular diagnostic kits for evaluating stress
WO2020081714A1 (en) * 2018-10-16 2020-04-23 Board Of Regents, The University Of Texas System Identification and targeting of pathogenic extracellular matrix for diagnosis and treatment of cancer and other diseases
EP3873521A2 (en) 2018-10-31 2021-09-08 Tiziana Life Sciences PLC Composition and methods of treating inflammatory and autoimmune diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025477A (en) * 1986-03-31 2000-02-15 Calenoff; Emanuel Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US7041289B1 (en) * 1997-12-05 2006-05-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for treating established spontaneous auto-immune diseases in mammals
GB2380127A (en) * 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
US20030216551A1 (en) * 2002-03-08 2003-11-20 Diabetogen Biosciences Inc. Fully human anti-CD3 monoclonal antibodies
JP2007538000A (ja) * 2004-01-08 2007-12-27 リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 制御性ｔ細胞は自己免疫を抑制する

Also Published As

Publication number Publication date
KR20070036035A (ko) 2007-04-02
ZA200608884B (en) 2008-06-25
ES2348984T3 (es) 2010-12-21
CA2563260A1 (en) 2005-10-27
CN1972714A (zh) 2007-05-30
IL209338A0 (en) 2011-01-31
CA2563260C (en) 2013-05-28
CN102847149A (zh) 2013-01-02
JP4812748B2 (ja) 2011-11-09
EP1737490A2 (en) 2007-01-03
NO340627B1 (no) 2017-05-15
CN1972714B (zh) 2012-10-03
CN102847149B (zh) 2016-01-20
UA103594C2 (ru) 2013-11-11
PT1737490E (pt) 2010-08-31
US20050265993A1 (en) 2005-12-01
WO2005099755A2 (en) 2005-10-27
DE602005021766D1 (de) 2010-07-22
NO20064896L (no) 2006-11-06
EA012725B1 (ru) 2009-12-30
EA200601871A1 (ru) 2007-04-27
MXPA06011526A (es) 2007-03-21
NO20170737A1 (no) 2006-11-06
AU2005232653A1 (en) 2005-10-27
HK1099525A1 (en) 2007-08-17
JP2007532565A (ja) 2007-11-15
WO2005099755A3 (en) 2006-04-27
IL178478A (en) 2010-12-30
DK1737490T3 (da) 2010-10-04
EP1737490B1 (en) 2010-06-09
AU2005232653B2 (en) 2010-12-16
IL178478A0 (en) 2007-02-11
ATE470453T1 (de) 2010-06-15

Similar Documents

Publication Publication Date Title
UA89780C2 (ru) Способ лечения или облегчения симптомов атеросклероза с помощью анти-cd3 антитела
WO2005007192A3 (en) Cytoprotection through the use of hif hydroxylase inhibitors
UA92505C2 (ru) Композиции на основе антитела против cd3
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
MY147217A (en) Antibody molecules having specificity for human il-06
MY154984A (en) Preventing autoimmune disease
TW200738270A (en) Method of treating depression using a TNFα antibody
MX2007001035A (es) Metodo para producir una composicion, la composicion y su uso.
WO2006116423A3 (en) Compositions and methods for cancer immunotherapy
WO2008154423A3 (en) Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
MX2009005004A (es) Microorganismos o fracciones de los mismos capaces de activar inmunidad celular contra carbohidratos.
WO2009126934A3 (en) Detection and tratment of pancreatic, ovarian and other cancers
MX2010006823A (es) Metodos para el tratamiento de la gota.
UA104132C2 (en) Humanized antibodies against tl1a
SG132645A1 (en) Process for the production of polyols based on natural oils
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MX2007011668A (es) Mezclas de caucho de silicona de reticulacion por adicion autoadhesivas, metodo para la produccion de las mismas, metodo para producir partes moldeadas compuestas y uso de las mismas.
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
NO20092652L (no) Konstruert anti-TSLP-antistoff
WO2004099249A3 (en) Optimized fc variants and methods for their generation
CY1108602T1 (el) Μεθοδος καθαρισμου της fsh
WO2006000547A3 (de) Verfahren zur herstellung eines phosphatadsorbens auf eisensulfat-basis
TW200613256A (en) Photoactive compounds
TW200700071A (en) Novel use